Initial Experience with CD19/CD22 BiCistronic CAR T-Cells in Children and Young Adults with Recurrent or Refractory B-Cell Malignancies
Brynn B. Duncan(Center for Cancer Research), Nirali N. Shah(National Institutes of Health), Alexander W. Rankin(National Institutes of Health), Jon R. Inglefield(Frederick National Laboratory for Cancer Research), Toni Foley, Naomi Taylor(National Institutes of Health), John A. Ligon(University of Florida Health), Bonnie Yates(National Institutes of Health), Sara Silbert(National Institutes of Health), Haneen Shalabi(Center for Cancer Research), David F. Stroncek(Yale University), Lauren Little(Rush University), Hao‐Wei Wang(Fu Jen Catholic University), Yanyu Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Steven L. Highfill(National Institutes of Health), Hannah Song(University of Wisconsin–Madison), Constance M. Yuan(National Cancer Institute)
Cited by 4
Related Papers
IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion
|Genes & Development|2010|744
Hypoxia-enhanced Blood-Brain Barrier Chip recapitulates human barrier function and shuttling of drugs and antibodies
|Nature Communications|2019|595
CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial
|Journal of Clinical Oncology|2020|422
Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion
|Nature Reviews Clinical Oncology|2022|324